New Study Investigating Long-term Safety, Effectiveness of Reldesemtiv
A new study is investigating the longer-term effects — over a one-year period — of the therapy candidate reldesemtiv in people with amyotrophic lateral sclerosis (ALS). Cytokinetics has launched an open-label extension (OLE) study to evaluate the safety and effectiveness of reldesemtiv over a longer course in patients…